Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer

Sandra Blasco-Benito, Estefanía Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, María M. Caffarel, Miriam Caro-Villalobos, Leyre Urigüen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucía Hernández, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernadó-Morales, Joaquín Arribas, Meritxell Canals, Vicent Casadó, Enric Isidre CanelaManuel Guzmán, Eduardo Pérez-Gómez, Cristina Sánchez

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)
13 Downloads (Pure)


There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2–CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer.
Original languageEnglish
Pages (from-to)3863-3872
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America (PNAS)
Issue number9
Early online date7 Feb 2019
Publication statusPublished - 26 Feb 2019

Cite this